Panel Discussion: Evaluating Safety & CMC Expectations between Different Cell Therapy Types & Autoimmune Indications
Moderator – Fred Aslan, Chief Executive Officer, Artiva Biotherapeutics
Time: 8:30 am
day: Day Two AM
Details:
• Discussing the advantages and disadvantages of different cell therapy modalities when meeting CMC expectations
• Understanding safety parameters that need to be demonstrated and how those may differ in various autoimmune indications
• What are some of the standards that are set or need to be set for cell therapies to advance in the autoimmune space?
• What are some of the regulatory requirements that are unique in the autoimmune space as opposed to oncology which may be challenging?
